Avantor (NYSE:AVTR) Price Target Cut to $25.00 by Analysts at Morgan Stanley

Avantor (NYSE:AVTR) had its price target dropped by equities research analysts at Morgan Stanley from $27.00 to $25.00 in a report released on Monday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Morgan Stanley’s target price points to a potential upside of 32.45% from the company’s previous close.

AVTR has been the subject of several other reports. Stifel Nicolaus reduced their target price on Avantor from $28.00 to $26.00 and set a “buy” rating for the company in a report on Monday. Wells Fargo & Company decreased their target price on Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a research report on Monday. Royal Bank of Canada cut their price target on Avantor from $33.00 to $31.00 and set an “outperform” rating for the company in a research note on Monday. Barclays cut their price objective on shares of Avantor from $26.00 to $23.00 and set an “overweight” rating for the company in a report on Monday. Finally, Raymond James reaffirmed an “outperform” rating and set a $24.00 price objective (down previously from $26.00) on shares of Avantor in a research note on Monday. Three investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $26.15.

Avantor Trading Down 1.5 %

Shares of NYSE AVTR traded down $0.29 during midday trading on Monday, reaching $18.88. The stock had a trading volume of 4,748,677 shares, compared to its average volume of 5,169,108. The company’s 50 day moving average price is $21.73 and its 200 day moving average price is $23.47. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.06 and a current ratio of 1.54. Avantor has a twelve month low of $18.49 and a twelve month high of $28.00. The firm has a market cap of $12.85 billion, a price-to-earnings ratio of 41.00, a price-to-earnings-growth ratio of 3.87 and a beta of 1.28.

Avantor (NYSE:AVTR) last released its quarterly earnings data on Wednesday, February 12th. The company reported $0.27 EPS for the quarter, beating the consensus estimate of $0.26 by $0.01. Avantor had a return on equity of 12.24% and a net margin of 4.54%. During the same quarter in the prior year, the business earned $0.22 earnings per share. As a group, sell-side analysts expect that Avantor will post 0.98 EPS for the current year.

Institutional Trading of Avantor

Hedge funds and other institutional investors have recently bought and sold shares of the stock. MassMutual Private Wealth & Trust FSB boosted its position in Avantor by 99.5% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,253 shares of the company’s stock valued at $26,000 after buying an additional 625 shares during the period. Smartleaf Asset Management LLC increased its position in Avantor by 106.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,611 shares of the company’s stock valued at $34,000 after purchasing an additional 830 shares during the period. UMB Bank n.a. bought a new position in Avantor in the third quarter worth about $49,000. Global Retirement Partners LLC lifted its holdings in Avantor by 76.7% in the fourth quarter. Global Retirement Partners LLC now owns 2,459 shares of the company’s stock worth $52,000 after buying an additional 1,067 shares during the period. Finally, Nisa Investment Advisors LLC boosted its position in Avantor by 69.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company’s stock valued at $53,000 after acquiring an additional 835 shares in the last quarter. Institutional investors own 95.08% of the company’s stock.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.